Literature DB >> 17215280

Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.

Joe Grove1, Thierry Huby, Zania Stamataki, Thomas Vanwolleghem, Philip Meuleman, Michelle Farquhar, Anne Schwarz, Martine Moreau, James S Owen, Geert Leroux-Roels, Peter Balfe, Jane A McKeating.   

Abstract

Hepatitis C virus (HCV) enters cells via a pH- and clathrin-dependent endocytic pathway. Scavenger receptor BI (SR-BI) and CD81 are important entry factors for HCV internalization into target cells. The SR-BI gene gives rise to at least two mRNA splice variants, SR-BI and SR-BII, which differ in their C termini. SR-BI internalization remains poorly understood, but SR-BII is reported to endocytose via a clathrin-dependent pathway, making it an attractive target for HCV internalization. We demonstrate that HCV soluble E2 can interact with human SR-BI and SR-BII. Increased expression of SR-BI and SR-BII in the Huh-7.5 hepatoma cell line enhanced HCV strain J6/JFH and JFH infectivity, suggesting that endogenous levels of these receptors limit infection. Elevated expression of SR-BI, but not SR-BII, increased the rate of J6/JFH infection, which may reflect altered intracellular trafficking of the splice variants. In human plasma, HCV particles have been reported to be complexed with lipoproteins, suggesting an indirect interaction of the virus with SR-BI and other lipoprotein receptors. Plasma from J6/JFH-infected uPA-SCID mice transplanted with human hepatocytes demonstrates an increased infectivity for SR-BI/II-overexpressing Huh-7.5 cells. Plasma-derived J6/JFH infectivity was inhibited by an anti-E2 monoclonal antibody, suggesting that plasma virus interaction with SR-BI was glycoprotein dependent. Finally, anti-SR-BI antibodies inhibited the infectivity of cell culture- and plasma-derived J6/JFH, suggesting a critical role for SR-BI/II in HCV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215280      PMCID: PMC1866051          DOI: 10.1128/JVI.02356-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.

Authors:  Philip Meuleman; Louis Libbrecht; Rita De Vos; Bernard de Hemptinne; Kris Gevaert; Joël Vandekerckhove; Tania Roskams; Geert Leroux-Roels
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

2.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

3.  An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Authors:  Birke Bartosch; Géraldine Verney; Marlène Dreux; Peggy Donot; Yoann Morice; François Penin; Jean-Michel Pawlotsky; Dimitri Lavillette; Francois-Loïc Cosset
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI.

Authors:  Thomas J F Nieland; Marcelo Ehrlich; Monty Krieger; Tomas Kirchhausen
Journal:  Biochim Biophys Acta       Date:  2005-03-09

5.  Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Authors:  Dimitri Lavillette; Alexander W Tarr; Cécile Voisset; Peggy Donot; Birke Bartosch; Christine Bain; Arvind H Patel; Jean Dubuisson; Jonathan K Ball; François-Loïc Cosset
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

6.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

7.  High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

Authors:  Cécile Voisset; Nathalie Callens; Emmanuelle Blanchard; Anne Op De Beeck; Jean Dubuisson; Ngoc Vu-Dac
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

8.  The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses.

Authors:  N Bannert; D Schenten; S Craig; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

10.  Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion.

Authors:  Angela M Domitrovich; Daniel J Felmlee; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

View more
  70 in total

1.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

Review 2.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 3.  Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions.

Authors:  Wen-Jun Shen; Jie Hu; Zhigang Hu; Fredric B Kraemer; Salman Azhar
Journal:  Metabolism       Date:  2014-03-21       Impact factor: 8.694

4.  Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display.

Authors:  Fang Chen; Yinglan Zhao; Min Liu; Dongqing Li; Hongyan Wu; Haidan Chen; Yongzhe Zhu; Fengling Luo; Jin Zhong; Yidan Zhou; Zhongtian Qi; Xiao-Lian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 5.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

6.  Residues in a highly conserved claudin-1 motif are required for hepatitis C virus entry and mediate the formation of cell-cell contacts.

Authors:  Lisa Cukierman; Laurent Meertens; Claire Bertaux; Francis Kajumo; Tatjana Dragic
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

7.  Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.

Authors:  Anne K Schwarz; Joe Grove; Ke Hu; Christopher J Mee; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

8.  Effect of cell polarization on hepatitis C virus entry.

Authors:  Christopher J Mee; Joe Grove; Helen J Harris; Ke Hu; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.

Authors:  Katharina B Rothwangl; Lijun Rong
Journal:  Virol J       Date:  2009-01-26       Impact factor: 4.099

10.  Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Authors:  Marlène Dreux; Viet Loan Dao Thi; Judith Fresquet; Maryse Guérin; Zélie Julia; Géraldine Verney; David Durantel; Fabien Zoulim; Dimitri Lavillette; François-Loïc Cosset; Birke Bartosch
Journal:  PLoS Pathog       Date:  2009-02-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.